ClinicalTrials.gg
CompletedNCT05378555Updated Sep 28, 2026

Oral Ketamine for Treatment of Vaso-Occlusive Pain

A Phase 1 interventional study of Ketamine Hydrochloride in Vaso-occlusive Crisis, sponsored by Boston Children's Hospital. Completed at 1 site in United States. Open to participants aged 12 Years to 24 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Boston Children's Hospital · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.
Updated Sep 28, 2026Now CompletedStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
12 Years to 24 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Vaso-Occlusive Crises with a site in United States — 13 open to participants now, 15 under way, 5 of them phase 3. Vaso-Occlusive Crises · United States.

Enrollment
47th of 56
10 · median 63
Started
2023
with 1 other
Phase 1
4 of 60
1 open now
Registered
45th of 60
by date
Lead sponsor
3 of 60
Boston Children's Hospital

Among the 60 studies in Vaso-Occlusive Crises with a site in United States, this one is the 47th largest by enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2023, is one of 4 in phase 1, and was the 45th registered.

Vaso-Occlusive Crises

104 studies on the registry are indexed under Vaso-Occlusive Crises; 31 are open to participants now.

Browse Vaso-Occlusive Crises studies →

Open to participants now

13 of the 60 studies in Vaso-Occlusive Crises with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Vaso-Occlusive Crises studies recruiting now, 7 (41%) set no upper age limit and 6 (35%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.

This study: 12 Years to 24 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Vaso-Occlusive Crises with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to learn more about the feasibility of oral ketamine for the treatment of painful sickle-cell crises in children and adolescents as a supplement to intravenous (IV) opioids. There is a need for improved non-opioid analgesia for patients experiencing sickle-cell crises in the hospital and prehospital setting, as children and adolescents with sickle cell disease who experience sickle-cell crises often have severe pain that is not well controlled by high dose opioids, leading to poor pain management and opioid-related side effects.

The study will begin when patients are admitted to the Emergency Department of Boston Children's Hospital for treatment of a sickle-cell crisis. Oral ketamine will be administered every 8 hours for the next 48 hours. Patients will have continuous cardiorespiratory monitoring for the duration of the study, as per routine care, as well as monitoring by the hospital's Acute Pain Service at least twice daily for pain management and side effects of pain treatment.

At the end of the 48-hour study duration, patients will discuss with the Pain Service and Hematology Service whether to continue oral ketamine, change to intravenous ketamine, or discontinue ketamine based on clinical indications such as level of pain and sedation while on opioids.

Read the detailed description

This is a pilot study of the feasibility of oral ketamine dosing initiated in the Emergency Department and continued for 48 hours for adolescents and young adults hospitalized with VOCs. A total of 10 patients between the ages of 12 and 24 years will receive oral ketamine 0.5 mg/kg Q8hrs for 48 hours.

Pain scores using VAS and Modified Ramsey Sedation Scores will be obtained every 4 hours per routine nursing care. Vital signs (temperature, heart rate, blood pressure, and respiratory rate) will also be taken every 4 hours throughout the study duration. Side effects (such as dysphoria, dizziness, unpleasant dreams, hallucinations, headache, and nausea) will be monitored throughout the study duration. The Acute Pain Service will assess each patient at least twice daily for pain management and side effects to pain treatment. Ketamine will be discontinued for patients who experience side effects. Patients who experience continued high pain scores will have the option of having oral ketamine discontinued and IV ketamine infusion initiated.

At the end of the 48 hour study period, patient, parent, Pain Service and Hematology Service will discuss whether to continue oral ketamine, change to intravenous ketamine, or discontinue ketamine based on clinical indications such as level of pain and sedation while on opioids. Patients and parents (for patients > 18 years) will be asked to complete a brief satisfaction survey at the end of the 48 hour study period.

Patients who are 12-24 years of age who require admission for vaso-occlusive pain will be included. Patients who do not wish to participate or who have had side effects to previous use of intravenous ketamine for treatment of vaso-occlusive pain that would preclude using ketamine for future pain episodes will not be included in this study.

03

Conditions studied

  • Vaso-occlusive Crisis

Keywords

  • Ketamine
  • Sickle-cell disease
  • Opioid-sparing
  • Analgesia
04

Who can participate

Ages eligible
12 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 12-24 years of age who require admission for vaso-occlusive pain

Exclusion criteria

Exclusion Criteria:

  • Patients who have had side effects to previous use of intravenous ketamine for treatment of vaso-occlusive pain that would preclude using ketamine for future pain episodes.
  • Patient refusal to participate
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Ketamine

    Drug: Ketamine Hydrochloride

Interventions

  • DrugKetamineStudies of KetamineKetamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All patients in this study will receive oral ketamine for the treatment of pain from vaso-occlusive crisis. Patients will receive 0.5 mg/kg ketamine Q8hrs for 48 hours.

06

What researchers measure

Primary outcomes

  1. Change in pain intensity scores using the Visual Analogue Scale (VAS) Pain Score Scale

    The Visual Analog Scale (VAS) will be used to measure pain. Scores are recorded on a line that represents a continuum between "no pain" and "worst pain."

    Time frame: Baseline, and then every 4 hours for 48 hours

Secondary outcomes

  1. Change in Sedation Scores using modified Ramsey Sedation Scores Scale

    The Ramsay Sedation Scale used as a measure of sedation allows for a numeric score from 1 to 6, based on responsiveness of the patient. The scale divides a patient's level of sedation into six categories ranging from severe agitation to deep coma.

    Time frame: Baseline, and then every 4 hours for 48 hours

  2. Number of patients with abnormal vital signs

    Vital signs data (blood pressure, heart rate, respiratory rate, and temperature) will be collected and number of patients with abnormal vital signs will be reported.

    Time frame: Baseline, and then every 4 hours for 48 hours

  3. Frequency of side effects

    Side effects such as dysphoria, dizziness, unpleasant dreams, hallucinations, headache, nausea will be assessed.

    Time frame: Baseline, and then every 4 hours for 48 hours

07

Study locations

1 site
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
08

References and documents

Publications

  • Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017 Jul 15;390(10091):311-323. doi: 10.1016/S0140-6736(17)30193-9. Epub 2017 Feb 1. PubMed 28159390 ↗
  • Neri C, Pestieau S, Young H, Elmi A, et al. Low-dose ketamine for children and adolescents with acute sickle cell disease related pain: a single center experience. J Anesth Clin Res 2014.
  • Telfer P, Kaya B. Optimizing the care model for an uncomplicated acute pain episode in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):525-533. doi: 10.1182/asheducation-2017.1.525. PubMed 29222301 ↗
  • Lubega FA, DeSilva MS, Munube D, Nkwine R, Tumukunde J, Agaba PK, Nabukenya MT, Bulamba F, Luggya TS. Low dose ketamine versus morphine for acute severe vaso occlusive pain in children: a randomized controlled trial. Scand J Pain. 2018 Jan 26;18(1):19-27. doi: 10.1515/sjpain-2017-0140. PubMed 29794277 ↗
  • Hagedorn JM, Monico EC. Ketamine Infusion for Pain Control in Acute Pediatric Sickle Cell Painful Crises. Pediatr Emerg Care. 2019 Jan;35(1):78-79. doi: 10.1097/PEC.0000000000000978. PubMed 27902670 ↗
  • Bredlau AL, McDermott MP, Adams HR, Dworkin RH, Venuto C, Fisher SG, Dolan JG, Korones DN. Oral ketamine for children with chronic pain: a pilot phase 1 study. J Pediatr. 2013 Jul;163(1):194-200.e1. doi: 10.1016/j.jpeds.2012.12.077. Epub 2013 Feb 10. PubMed 23403253 ↗
  • Fallon MT, Wilcock A, Kelly CA, Paul J, Lewsley LA, Norrie J, Laird BJA. Oral Ketamine vs Placebo in Patients With Cancer-Related Neuropathic Pain: A Randomized Clinical Trial. JAMA Oncol. 2018 Jun 1;4(6):870-872. doi: 10.1001/jamaoncol.2018.0131. PubMed 29621378 ↗
  • Rosenblat JD, Carvalho AF, Li M, Lee Y, Subramanieapillai M, McIntyre RS. Oral Ketamine for Depression: A Systematic Review. J Clin Psychiatry. 2019 Apr 16;80(3):18r12475. doi: 10.4088/JCP.18r12475. PubMed 30995364 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2023 to primary completion in Nov 2025, 29 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Jun 2026 → Nov 2025 and completion Jun 2026 → Nov 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2022
First posted
May 18, 2022
StartActual
May 26, 2023
Primary completionActual
Nov 21, 2025was Jun 2026
CompletionActual
Nov 21, 2025was Jun 2026
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 28, 2026
Start date
May 1, 2023→May 26, 2023
Sep 28, 2026
Primary completion
Jun 2026→Nov 21, 2025 (actual)
Sep 28, 2026
Study completion
Jun 1, 2026→Nov 21, 2025 (actual)
Sep 28, 2026
Design
Phase 3→Phase 1
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Recruiting→Completed
    Start date May 1, 2023→May 26, 2023
    Primary completion Jun 2026→Nov 21, 2025 (now actual)
    Study completion Jun 1, 2026→Nov 21, 2025 (now actual)
    Design Phase 3→Phase 1
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05378555
Responsible party
Christine Greco (Chief, Division of Pain Medicine, Boston Children's Hospital) — Principal investigator
First posted
May 18, 2022
Start date
May 26, 2023
Primary completion
Nov 21, 2025
Completion
Nov 21, 2025
Last update
Sep 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion